Travoprost ( @entity33312 (  )), a prostaglandin ophthalmic solution, is a second-line therapy for @entity1538 , according to the Clinical Practice Guideline of the American Optometric Association. Recently, travoprost has been used as a first-line therapy in many @entity1 because of its effectiveness and a once-daily dosing. It lowers the intraocular pressure by enhancing the aqueous humor outflow. Based on the product information, adverse effects such as @entity2194 , @entity3856 , @entity111 , and @entity1168 have been associated with travoprost therapy. Significant @entity1168 is defined as heart rate or pulse of less than 60 beats per minute. We report on an 87-year-old @entity1 who experienced asymptomatic @entity1168 while using travoprost ophthalmic solution. The pulse in our @entity1 ranged from 42 to 50 beats per minute while receiving travoprost therapy during his hospitalization. Travoprost ophthalmic solution was discontinued because it was thought to be the likely cause of significant sinus @entity1168 in our @entity1 . After travoprost discontinuation, the average pulse of the @entity1 was 66 beats per minute. Based on Naranjo's Scoring System (an objective tool) for assessing the likelihood of drug-induced adverse effects, the score of 3 was obtained, which indicated a "possible" adverse effect. To our knowledge, this is the first case report about significant @entity1168 possibly associated with travoprost therapy.

Asymptomatic XXXX possibly associated with travoprost therapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'man'] @entity2194 :: ('MESH:D005128', 'Disease') :: ['ocular hyperemia'] @entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma'] @entity111 :: ('MESH:D011537', 'Disease') :: ['pruritus'] @entity3856 :: ('MESH:D058447', 'Disease') :: ['eye pain'] @entity33312 :: ('MESH:C438103', 'Chemical') :: ['Travatan'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']
@entity1168 :: (MESH:D001919,Disease) :: ['bradycardia']
